299 related articles for article (PubMed ID: 30935657)
1. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
2. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
3. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
[TBL] [Abstract][Full Text] [Related]
4. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
Jackson TL; Regillo CD; Girach A; Dugel PU;
Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
[TBL] [Abstract][Full Text] [Related]
5. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
6. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
[TBL] [Abstract][Full Text] [Related]
7. Ocriplasmin for symptomatic vitreomacular adhesion.
Neffendorf JE; Kirthi V; Pringle E; Jackson TL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial.
Lavine JA; Srivastava SK; Dukles N; Reese JL; Ehlers JP
Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879
[TBL] [Abstract][Full Text] [Related]
9. OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.
Steel DHW; Patton N; Stappler T; Karia N; Hoerauf H; Patel N; Wachtlin J; Raber T; Kozma-Wiebe P;
Retina; 2021 Feb; 41(2):266-276. PubMed ID: 32496343
[TBL] [Abstract][Full Text] [Related]
10. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
[TBL] [Abstract][Full Text] [Related]
11. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
[TBL] [Abstract][Full Text] [Related]
12. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
[TBL] [Abstract][Full Text] [Related]
13. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
Manousaridis K; Peter-Reichart S; Mennel S
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
[TBL] [Abstract][Full Text] [Related]
14. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
[TBL] [Abstract][Full Text] [Related]
15. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
[TBL] [Abstract][Full Text] [Related]
16. Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting.
Wertheimer C; Haritoglou C; Laubichler P; Wolf A; Kaessmann K; Schumann RG; Priglinger S; Mayer WJ
Ophthalmologica; 2018; 239(1):11-18. PubMed ID: 28954271
[TBL] [Abstract][Full Text] [Related]
17. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
[TBL] [Abstract][Full Text] [Related]
18. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
[No Abstract] [Full Text] [Related]
19. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
[TBL] [Abstract][Full Text] [Related]
20. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.
Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S
Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
